Pettiti Gianluca sold $2.9M of TMO

Pettiti Gianluca (President & COO) sold 4,133 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at $701.42 ($2.90M total) across 2 trades on 2026-11-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Pettiti Gianluca
Published Nov 16, 2026, 9:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TMO
Neutral
medium confidence
Mentioned
$TMO
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

The disclosed open-market sale reduces the executive’s direct holdings but is framed as pre-arranged under Rule 10b5-1, which typically dampens informational content.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to drive a major repricing without accompanying operational or guidance news.

03

What to watch

The filing does not indicate any change in business outlook, only that the executive reduced holdings; traders may overreact if they ignore the 10b5-1 context.

Relevance 5/10Novelty 6/10Timing: Form 4 filed 2026-11-16, covering sales executed 2026-11-13.

Background

The article is an SEC Form 4 insider transaction disclosure for Thermo Fisher Scientific, reported by its President & COO.

Company-level read

Ticker impact

$TMONeutralMedium confidence
Context

Thermo Fisher COO Gianluca Pettiti sold $2.9M of TMO shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact as the sale is pre-arranged under a 10b5-1 plan, though it can slightly pressure sentiment.

Evidence & confidence

The filing is a primary Form 4 disclosure with clear size ($2.9M) and role (President & COO), but 10b5-1 typically indicates planned diversification rather than new negative information.

Market effects

No clear sector read-through; this is company-specific insider activity.

None.

None.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish fundamentals.

Key entities

  • Thermo Fisher Scientific

    Subject of the Form 4 insider sale by President & COO Gianluca Pettiti.

  • Pettiti Gianluca

    President & COO who sold 4,133 shares for about $2.9M under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TMOMed

Thermo Fisher Scientific Replenishes Buyback Capacity to $5 Billion

Thermo Fisher Scientific (TMO) authorized up to $5B in new stock repurchases, replacing a prior authorization with $1B remaining. The company spent $4B on buybacks in 2026's first nine months, with no purchases in Q3. Operating cash flow increased to $5.867B for the period, with $4.618B in free cash flow. The new authorization complements acquisitions, dividends, and debt obligations.